NRGBiotic (magnesium orotate/ coenzyme Q10/ probiotic strains) / Medlab Clinical - LARVOL DELTA

US Patent Office issues Notice of Allowance status for NRGBiotic for treating, preventing, or Ameliorating depression or a Depressive disorder (GlobeNewswire) - P1, N=NA; "Medlab Clinical Ltd...announce the United States Patent Office (USPTO) has issued a Notice of Allowance for Application number 15/523,271 for the formulation known as NRGBiotic™...The patent covers both the formulation of NRGBiotic™ and a method for treating, preventing, or ameliorating at least one symptom of depression or a depressive disorder and is valid through to 28 October 2035....Participants taking both NRGBiotic™, and an anti-depressant had greater symptom remission over the 8 weeks period than those on an anti-depressant alone (p=0.015). Incidence of dysbiosis assessed by faecal analysis showed both groups were dysbiotic, holding to the premise that anti-depressant medications adversely affect the intestinal bacteria leading to an unbalanced dysbiotic gut."

P1 data • Patent • CNS Disorders • Depression • Major Depressive Disorder

"$MDC US Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder. https://t.co/95jD6aOIDw" (@otcdynamics)

CNS Disorders • Depression • Mood Disorders • Psychiatry

Medlab Clinical completes NRGBiotic depression trial (Proactiveinvestors) - "The medical life science company received a government grant of $75,000 for the clinical depression trial, which was conducted at the Queensland University of Technology. Medlab Clinical Ltd...shares rose almost 16% upon completing...trial for depression using its NRGBiotic™ product. The trial closed at 120 patients and aimed to follow-on from previous trials investigating the use of NRGBiotic™ versus placebo....Medlab expects that results publication and doctor/pharmacist education, as well as undertaking heightened dialogue with the Therapeutic Goods Administration, will determine the next potential steps."

Grant • Stock price • Trial completion

Medlab Clinical ahead of expectations with phase 2 depression trial for NRGBiotic (Proactiveinvestors) - "Medlab Clinical Ltd...is progressing ahead of expectations with a Phase 2 Depression Trial using a unique self-branded, in pharmacy formulation, NRGBiotic™ from its Nutraceuticals range. Current results are suggesting the trial will complete earlier than originally required."

Trial status

Heads of agreement executed to expand nutraceutical business in the USA (Medlab Clinical Press Release) - "Australian medical life sciences company, Medlab Clinical Ltd...announce that it has signed a Heads of Agreement with ANC for a US market entry using MDC’s existing nutraceuticals...Key nutraceutical products of interest include Medlab’s heavily researched NanoCelle™ delivery platform, NRGBiotic™, currently used in ongoing Depression trials..."

Licensing / partnership